Description
AI Overview
Kisqali 200 mg tablets contain the active ingredient ribociclib, which is a targeted therapy known as a CDK4/6 inhibitor. It is prescribed to treat certain types of hormone receptor (HR)-positive, HER2-negative breast cancer (both early and advanced/metastatic) by blocking proteins that drive cancer cell division and growth. [1, 2, 3]
Key Details & Administration
- How it is taken: Orally, with or without food. It is almost always combined with an endocrine/hormonal therapy (such as an aromatase inhibitor or fulvestrant). [1]
- Treatment Cycle: The tablets are typically taken once daily for 21 consecutive days, followed by a 7-day break to complete a 28-day cycle. [1]
Reviews
There are no reviews yet.